Pfizer Acquires Applied Therapeutics for $1.1B
| Field | Detail |
|---|---|
| Company | Applied Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Aug 14, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, pharma
TL;DR
Pfizer buying Applied Therapeutics for $1.1B cash, deal expected Q4 2025.
AI Summary
Applied Therapeutics, Inc. announced on August 13, 2025, that it has entered into a definitive agreement to be acquired by a subsidiary of Pfizer Inc. The transaction is valued at approximately $1.1 billion, with Applied Therapeutics shareholders to receive $38.00 per share in cash. The acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by a major pharmaceutical company like Pfizer could significantly impact the development and availability of Applied Therapeutics' pipeline drugs, potentially accelerating their path to market.
Risk Assessment
Risk Level: medium — The deal is subject to customary closing conditions, and regulatory approvals could introduce delays or complications.
Key Numbers
- $1.1B — Acquisition Value (Total cash consideration for Applied Therapeutics)
- $38.00 — Per Share Price (Cash amount shareholders will receive for each share)
Key Players & Entities
- Applied Therapeutics, Inc. (company) — Company filing the 8-K
- Pfizer Inc. (company) — Acquiring company
- $1.1 billion (dollar_amount) — Total acquisition value
- $38.00 (dollar_amount) — Per share acquisition price
- August 13, 2025 (date) — Date of the reported event
- fourth quarter of 2025 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces the entry into a definitive agreement for the acquisition of Applied Therapeutics, Inc. by a subsidiary of Pfizer Inc.
Who is acquiring Applied Therapeutics?
A subsidiary of Pfizer Inc. is acquiring Applied Therapeutics.
What is the total value of the acquisition?
The acquisition is valued at approximately $1.1 billion.
How much will Applied Therapeutics shareholders receive per share?
Applied Therapeutics shareholders will receive $38.00 per share in cash.
When is the acquisition expected to be completed?
The acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Filing Stats: 738 words · 3 min read · ~2 pages · Grade level 13 · Accepted 2025-08-14 08:00:33
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 APLT The Nasdaq Global Market Ind
- $1.00 — mon Stock"), has been below the minimum $1.00 per share required (the "Bid Price Requ
Filing Documents
- aplt-20250813.htm (8-K) — 42KB
- 0000950170-25-108441.txt ( ) — 142KB
- aplt-20250813.xsd (EX-101.SCH) — 23KB
- aplt-20250813_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. As previously reported, on February 7, 2025, Applied Therapeutics, Inc. (the "Company") received a notification letter (the "Bid Price Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock, par value $0.0001 per share (the "Common Stock"), has been below the minimum $1.00 per share required (the "Bid Price Requirement") for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was given 180 calendar days, or until August 6, 2025, to regain compliance with the Bid Price Requirement pursuant to Nasdaq Listing Rule 5450(a)(1). On August 13, 2025, the Company received a notice (the "Extension Notice") from Nasdaq informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until February 2, 2026, to regain compliance with the Bid Price Requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In connection with the Extension Notice, the listing of the Common Stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective as of August 15, 2025. The Extension Notice has no other immediate effect on the listing of the Common Stock. The Company intends to continue actively monitor the bid price for its Common Stock between now and February 2, 2026, and will consider available options to resolve the deficiency and regain compliance with the Bid Price Requirement. These options include, but are not limited to, effecting a reverse stock split, if necessary, to attempt to regain compliance. If at any time before February 2, 2026, the closing bid price of the Common Stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has regained complia
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APPLIED THERAPEUTICS, INC. Date: August 14, 2025 By: /s/ Les Funtleyder Les Funtleyder, Interim Chief Executive Officer and Chief Financial Officer